Utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid for differential diagnosis of primary lung cancer

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 14; no. 4; pp. 2443 - 2446
• Main Authors: Cao, Chao, Sun, Shi-Fang, Lv, Dan, Chen, Zhong-Bo, Ding, Qun-Li, Deng, Zai-Chun
• Format: Journal Article
• Language: English
• Published: Thailand 01.01.2013
• Subjects: Adenocarcinoma - diagnosis; Adenocarcinoma - metabolism; Biomarkers, Tumor - metabolism; Bronchoalveolar Lavage Fluid - chemistry; Carcinoma, Squamous Cell - diagnosis; Carcinoma, Squamous Cell - metabolism; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Lung Neoplasms - diagnosis; Lung Neoplasms - metabolism; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; ROC Curve; Small Cell Lung Carcinoma - diagnosis; Small Cell Lung Carcinoma - metabolism; Solitary Pulmonary Nodule - diagnosis; Solitary Pulmonary Nodule - metabolism; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A - metabolism; Vascular Endothelial Growth Factor Receptor-1 - metabolism
• ISSN: 1513-7368; 2476-762X
• DOI: 10.7314/APJCP.2013.14.4.2443

Published data have shown that the levels of vascular endothelial growth factor (VEGF) and soluble VEGF receptor-1 (sVEGFR-1) in plasma and pleural effusion might be usefulness for lung cancer diagnosis. Here, we performed a prospective study to investigate the utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid (BALF) for differential diagnosis of primary lung cancer. A total of 56 patients with solitary pulmonary massed by chest radiograph or CT screening were enrolled in this study. BALF and plasma samples were obtained from all patients and analyzed for VEGF and sVEGFR-1 using a commercially available sandwich ELISA kit. The results showed that the levels of VEGF in BALF were significantly higher in patients with a malignant pulmonary mass compared with patients with a benign mass (P < 0.001). However, no significant difference of sVEGFR-1 in BALF was found between malignant and non-malignant groups (P = 0.43). With a cut-off value of 214 pg/ml, VEGF showed a sensitivity and specificity of 81.8% and 84.2%, respectively, in predicting the malignant nature of a solitary pulmonary mass. Our study suggests that VEGF is significantly increased in BALF among patients with lung cancer than in benign diseases. Measurement of VEGF in BALF might be helpful for differential diagnosis of primary lung cancer.